Based on those data, venetoclax was administered either subcutaneously (SC, at 10 mg/kg or 20 mg/kg) or, due to abscess formation following repeated SC doses, as a combination of SC (20 mg/kg for the first two doses for each of the two 5-days treatment cycles) and OG (400 mg venclexta, the FDA-approved formulation of venetoclax, for the final three doses for each of the two 5-days treatment cycle) co-administered with the CYP3A inhibitor ketoconazole (10 mg/kg). This evidence concerns the gene CYP3A4 and abscess.